J. Richardson et al., Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus, J VIROLOGY, 73(5), 1999, pp. 3661-3671
Strains of the feline immunodeficiency virus (FIV) presently under investig
ation exhibit distinct patterns of in vitro tropism, In particular, the ada
ptation of FIV for propagation in Crandell feline kidney (CrFK) cells resul
ts in the selection of strains capable of forming syncytia,vith cell lines
of diverse species origin, The infection of CrFK cells by CrFK-adapted stra
ins appears to require the chemokine receptor CXCR4 and is inhibited by its
natural ligand, stromal cell-derived factor 1 alpha (SDF-1 alpha). Here ry
e found that inhibitors of CXCR4-mediated infection by human immunodeficien
cy virus type I (HIV-1), such as the bicyclam AMD3100 and short peptides de
rived from the amino-terminal region of SDF-1 alpha, also blocked infection
of CrFK by FN. Nevertheless, we observed differences in the ranking order
of the peptides as inhibitors of FIV and HIV-1 and showed that such differe
nces are related to the species origin of CXCR4 and not that of the viral e
nvelope, These results suggest that, although the envelope glycoproteins of
FIV and HIV-1 are substantially divergent, FIV and HIV-1 interact with CXC
R4 in a highly similar manner, We have also addressed the role of CXCR4 in
the life cycle of primary isolates of FIV, Various CXCR4 ligands inhibited
infection of feline peripheral blood mononuclear cells (PBMC) by primary FI
V isolates in a concentration-dependent manner. These ligands also blocked
the viral transduction of feline PBMC by pseudotyped viral particles when i
nfection was mediated by the envelope glycoprotein of a primary FIV isolate
but not by the G protein of vesicular stomatitis virus, indicating that th
ey act at an envelope-mediated step and presumably at viral entry. These fi
ndings strongly suggest that primary and CrFK-adapted strains of FIV, despi
te disparate in vitro tropisms, share usage of CXCR4.